GLIA Diagnostics

What GLIA Diagnostics does

GLIA Diagnostics Pty Ltd is an Australian biotechnology company developing a rapid point-of-care (POC) diagnostic platform for traumatic brain injury (TBI) and concussion. The platform applies proprietary microRNA (miRNA) biomarkers detected from a finger-stick blood sample to deliver objective biological assessment in minutes, targeting a diagnostic gap left by subjective clinical tools and by resource-intensive imaging modalities such as CT and MRI, which are poorly suited to frontline or sideline assessment.

The core technology combines cell-, tissue-, and disease-specific miRNA biomarkers (selected to cross the blood-brain barrier and to operate without a pre-injury baseline) with a portable, minimal-training platform. The miRNA panel is positioned to provide both diagnostic and prognostic insight across injury severity, supporting triage, treatment decisions, Return to Play/Work/Duty protocols, and longitudinal recovery monitoring. Validation is supported by five peer-reviewed studies, including prospective cohort work that identified altered miRNA in asymptomatic athletes and severity-graded biomarker changes in moderate-to-severe TBI.

GLIA targets four customer verticals: healthcare systems (emergency departments and hospitals), sports organizations (from youth through professional competition), military and defense (blast-related TBI and PTSD-adjacent use cases), and remote medicine. The company is pre-revenue and is advancing through regulatory and clinical validation. The intended go-to-market is direct enterprise sales to clinical and institutional buyers with global scope, while top-of-funnel awareness currently relies on website/blog content marketing and a Facebook presence. No pricing model, commercial customers, partnerships, or funding rounds are publicly disclosed.

Name

GLIA Diagnostics

Legal name

GLIA Diagnostics Pty Ltd

Website

https://gliadiagnostics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

GLIA Diagnostics is an Australian biotech developing a point-of-care platform for traumatic brain injury and concussion. It uses proprietary microRNA biomarkers from finger-stick blood samples to deliver objective assessment for healthcare, sports, military, and remote medicine.

Ownership category

akta.pro rank

Product category

Traumatic Brain Injury Diagnostics

NAICS

Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Traumatic brain injury diagnostics
• Point-of-care diagnostics
• MicroRNA biomarkers
• Concussion assessment
• Blood-based diagnostics

Headquarters

HQ city

Neutral Bay

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels2 records

Core offering

GLIA Diagnostics is developing a rapid point-of-care diagnostic platform for traumatic brain injury (TBI) and concussion assessment. The system combines proprietary microRNA (miRNA) biomarkers with portable hardware and analytics to deliver objective, biologically grounded diagnostic insight from a finger-stick blood sample in minutes. It is designed for use in emergency departments, athletic programs, military operations, and remote medicine, supporting triage, treatment decisions, longitudinal monitoring, and return-to-activity protocols.

Product overview

GLIA Diagnostics is developing a single unified product: the GLIA Diagnostics TBI Test, a rapid point-of-care diagnostic platform for traumatic brain injury (TBI) and concussion. The platform uses proprietary microRNA (miRNA) biomarkers detected from a finger-stick blood sample to provide objective, biologically grounded diagnostic insight in minutes. The technology is designed for use across clinical, sports, military, and remote medicine settings, supporting triage, treatment decisions, and return-to-activity protocols.

Differentiator

Problem solved

Functional benefit

Products and services

• GLIA Diagnostics TBI Test A rapid point-of-care diagnostic platform for traumatic brain injury (TBI) and concussion using proprietary microRNA (miRNA) biomarkers, delivering objective biological insights from a finger-stick blood sample in minutes. Designed for healthcare systems, athletic programs, military operations, and remote medicine settings to support rapid clinical decisions, longitudinal monitoring, and improved outcomes.

Quantifiable outcome

• 22% of athletes (17 of 77) with no recent concussion and no current symptoms showed significantly altered miRNA levels, suggesting vulnerability to mTBI and long-term molecular effects
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• BRAINBox Solutions: Clinical-stage diagnostics company developing a multimodal blood-based and neurocognitive test (BRAINBox TBI) for mild TBI/concussion. Most directly comparable peer given the same POC, blood-based, TBI-focused value proposition.
• Banyan Biomarkers: Developed the first FDA-cleared blood-based test for TBI (Banyan BTI / Brain Trauma Indicator, with partner Abbott). Directly comparable as a blood-based biomarker assay targeting concussion/TBI diagnosis.
• BioDirection: Developer of a portable blood-based concussion diagnostic (Tbit System) using biomarkers to detect and quantify TBI in minutes at the point of care. Closely aligned on POC, blood-based, minutes-level turnaround use case.

Broad incumbents

• Siemens Healthineers: Large diagnostics and imaging incumbent with POC blood analyzers (e.g., ADVIA Centaur, Atellica) used in hospital and ED settings. Comparable as a broad incumbent with the channel infrastructure to scale blood-based TBI tests globally.
• Bio-Rad Laboratories: Major life science and clinical diagnostics company offering immunoassay and multiplex platforms (e.g., Bio-Plex) used for biomarker research and clinical testing. Comparable as a diagnostics platform provider with overlapping biomarker/molecular assay capabilities.
• Cepheid (Danaher): Subsidiary of Danaher operating the GeneXpert molecular diagnostics platform used in hospitals and POC settings. Comparable as a molecular diagnostics platform owner with similar clinical-channel reach.
• QuidelOrtho: Merged diagnostics company offering immunoassay and rapid POC tests across hospital and ambulatory channels, including neurological and infectious disease assays. Comparable as a broad POC diagnostics incumbent with hospital channel overlap.
• Abbott Diagnostics: Global diagnostics incumbent operating the i-STAT and Alinity POC platforms, with an established TBI blood test partnership (Banyan BTI). Comparable as a POC diagnostics platform owner with overlapping TBI assay ambitions and global hospital reach.

Emerging players

• Quanterix: Developer of the Simoa ultra-sensitive single-molecule array platform, which is widely used to detect low-abundance blood biomarkers including for TBI/neurology research. Comparable as a high-sensitivity biomarker detection technology relevant to miRNA-based assays.
• Meso Scale Diagnostics: Provider of high-sensitivity multiplex immunoassay platforms (Meso Scale Discovery / MSD) widely used for biomarker validation in neurology and trauma research. Comparable as a multiplex diagnostics platform relevant to multi-analyte biomarker panels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/gliadiag
• Facebookfacebook.com/gliadiag

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GLIA Diagnostics